1. A yacht stabilizer comprising:
a vessel;
a stabilization system,
the stabilization system comprising a first strut,
the first strut movably attached to the transom of the vessel;
a first hydrofoil,
the first hydrofoil perpendicularly attached to said first strut;
wherein the first hydrofoil further comprises a second strut, the second strut having a first end and a second end; a mini foil, said mini foil having a top part and a bottom part; the first end of the second strut connected to the bottom part of the first hydrofoil and the bottom end of the second strut is perpendicularly attached to the top part of the mini foil; and
an active stabilization system,
the active stabilization system comprising:
a strut hole;
an actuator;
a vessel actuator mount;
a motion sensor,
a torque plate,
and a stabilization computer,
wherein the actuator is connected between the torque plate through the strut hole and to the vessel actuator mount,
the actuator is electrically connected to the stabilization computer, and the motion sensor is connected to the stabilization computer, whereby when the motion sensor senses a change of direction, the stabilization computer energizes the actuator to counteract the change of direction.
2. A method for improving yacht stabilization consisting of providing a means for measuring the displacement of a yacht from the level position providing a means for resisting the change from the level position wherein the means for resisting change is an actuator coupled with a hydrofoil and mounting the actuator to the transom of the yacht and the measuring and change resisting is performed while the hull of the yacht is resting in the water.
3. The method of claim 2 wherein the step of providing means for resisting change further comprises a minifoil, a minifoil fixably attached to the base of the hydrofoil.
4. A hydrofoil comprising:
a first strut, a hydrofoil, the hydrofoil perpendicularly attached to the first strut;
a split flap, the split flap having a front end and a rear end, the split flap movably connected to the front of the hydrofoil,
wherein the split flap further comprises a top part and a bottom part, a second strut, the second strut having a top part and a bottom part, and a mini foil, wherein the bottom part of the second strut is perpendicularly mounted to the mini foil and the top part of the second strut is mounted to the base of the bottom part of the split flap.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. An osmotic device for the delivery of venlafaxine and an anti-psychotic agent comprising:
a core comprising a therapeutically effective amount of VFX and at least one osmotic agent or osmopolymer;
a semipermeable membrane surrounding the core and having a passageway there through; and
an external coat comprising a therapeutically effective amount of an anti-psychotic agent;
wherein the core provides a controlled release of VFX, and at least 80% of the VFX is released within 13 hours after exposure of the osmotic device to an aqueous solution, and the external coat provides a rapid release of the anti-psychotic agent, and at least 75% of the anti-psychotic agent is released within 1 hour after exposure of the osmotic device to an aqueous solution.
2. The osmotic device of claim 1, wherein the external coat is applied by spraying a composition onto the semipermeable membrane.
3. The osmotic device of claim 1, wherein the external coat is compressed about and surrounds the semipermeable membrane.
4. The osmotic device of claim 1, wherein at least 75% of the anti-psychotic agent is released within about 40 minutes, and at least about 60% of the VFX is released within about 12 hours after administration.
5. The osmotic device of claim 1, wherein the release of at least one of the VFX and the anti-psychotic agent has a delayed onset.
6. The osmotic device of claim 1, wherein the anti-psychotic agent is selected from the group consisting of risperidone, olanzapine, clozapine, sertindole, ziprasidone, quetiapine, sulpiride, pimozide and clothiapine.
7. The osmotic device of claim 6, wherein the venlafaxine is administered once daily at a dose of 10-500 and the anti-psychotic agent is administered once daily at a dose of: a) risperidone5 to 10 mg per day; b) olanzapine5 to 20 mg, 0.25-50 mg, 1-30 mg, or 1-25 mg per day; c) clozapine100 to 400 mg, 12.5-900 mg, or 150-450 mg per day; d) sertindole15 to 20 mg per day or 0.0001 to 1.0 mgkg of body weight per day; e) ziprasidone80 to 160 mg, 5 to 500 mg or 50 to 100 mg per day; f) quetiapine150 to 600 mg or 1.0-40 mgkg of body weight per day; g) sulpiride50 to 100 mg per day; h) pimozide2 to 4 mg per day; or i) clothiapine-40 mg per day.
8. The osmotic device of claim 1, wherein the osmotic device delivers the anti-psychotic agent to the upper GI tract and the venlafaxine to the middle to lower GI tract.
9. The osmotic device of claim 1, wherein the osmotic device provides a VFX Cmax of about 17-23 ngml of plasma in a mammal.
10. The osmotic device of claim 9, wherein the osmotic device provides a VFX Tmax at about 7-11 hours.
11. The osmotic device of claim 1, wherein the osmotic device provides a VFX dissolution profile as follows:
9
Time (h)
Released (%)
STD (%)
1
7.2
1.3
3
23.6
0.5
5
43.3
2.1
7
59.0
2.3
9
69.7
2.1
11
77.0
1.8
13
81.8
1.7
15
84.7
1.7
19
88.1
1.4
23
90.8
1.5
12. The osmotic device of claim 11, wherein the osmotic device provides a single-dose VFX plasma concentration profile in a mammal as follows:
10
Mean VFX Plasma
Time (h)
Concentration (ngml)
S.E.M.
0
0.0
0.0
0.5
0.3
0.2
1
0.4
0.2
2
3.2
0.8
4
13.9
2.6
6
17.5
2.5
8
18.7
2.7
10
18.8
2.9
12
16.7
2.5
14
15.8
2.7
16
11.8
2.0
20
8.6
1.7
24
6.6
1.1
28
5.7
1.5
32
3.4
0.7
36
2.2
0.5
48
1.7
0.5
13. The osmotic device of claim 1, wherein the osmotic device provides a VFX Cmax of about 20-27 ngml of plasma in a mammal.
14. The osmotic device of claim 13, wherein the osmotic device provides a VFX Tmax at about 3.5-8.5 hours.
15. The osmotic device of claim 1, wherein the osmotic device provides a VFX release profile as follows:
11
Time (h)
Mean Released (%)
S.D. (%)
0
0
0
0.5
0.13
0.44
1
1.43
1.93
2
10.61
8.37
4
40.48
5.44
6
54.27
4.78
8
63.13
4.67
10
66.59
3.36
12
71.44
5.81
14
76.09
5.92
16
77.65
6.58
20
84.94
6.58
24
89.43
6.48
16. The osmotic device of claim 15, wherein the osmotic device provides a single-dose VFX plasma concentration profile in a mammal as follows:
12
Mean VFX Plasma
Time (h)
Concentration (ngml)
S.E.M.
0
0
0
0.5
0.2
0.2
1
1
0.4
2
6
1.6
4
21.2
3.1
6
22.6
3.3
8
21.3
4.0
10
16.8
2.9
12
15.4
3.3
14
13.4
2.8
16
9.6
1.5
20
8.9
2.5
24
6.5
1.5
28
4.6
1.1
32
3.7
1.0
36
3.1
0.9
48
1.3
0.3
17. The osmotic device of claim 1, wherein the osmotic device further comprises a first water soluble coat between the core and the semipermeable membrane.
18. The osmotic device of claim 17 comprising the following ingredients in the approximate amounts indicated:
13
Amount
INGREDIENT
(mg)
Core
Venlafaxine (salt or free form)
10-500
Osmagent
350-500
Binder
15-100
Plasticizer (lower molecular weight)
0.1-50
Plasticizer (higher molecular weight)
5-60
First water soluble coat
First water soluble polymer
8-15
Second water soluble polymer
5-25
Plasticizer (higher molecular weight)
0.2-4
Semipermeable membrane
Cellulose ester
40-75
Plasticizer (lower molecular weight)
0.5-13
External coat
Second water soluble polymer
5-30
Third water soluble polymer
3-15
Plasticizer (higher molecular weight)
1-6
19. The osmotic device of claim 17 further comprising a second water soluble coat between the semipermeable membrane and the external coat and an optional coat.
20. The osmotic device of claim 19 comprising the following ingredients in the approximate amounts indicated:
14
Amount
INGREDIENT
(mg)
Core
Venlafaxine (salt or free form)
10-500
Osmagent
175-250
Binder
7.5-50
Plasticizer (lower molecular weight)
0.1-25
Plasticizer (higher molecular weight)
2.5-30
First water soluble coat
First water soluble polymer
4-7.5
Second water soluble polymer
2.5-12.5
Plasticizer (higher molecular weight)
0.1-2
Semipermeable membrane
Cellulose ester
20-37.5
Plasticizer (lower molecular weight)
0.1-6.5
Second water soluble coat
First water soluble polymer
0.5-5
First opaquant
0.1-10
Second opaquant
1.0-15
External coat
Risperidone
0.25-20
Filler
280-500
Binder
15-60
Disintegrant
12-70
Optional exterior finish coat
Second water soluble polymer
8-30
Plasticizer (higher molecular weight)
0.5-8
21. A method of treating depression, anxiety andor psychosis in a mammal, the method comprising the step of administering an osmotic device according to any one of claims 1-20.